Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatment
Marzia Del Re(Saint Camillus International University of Health and Medical Sciences), Romano Danesi(University of Milan), Eleonora Rofi(University of Pisa), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Iacopo Petrini(University of Pisa), Paola Bordi, Francesca Mazzoni(Azienda Ospedaliero-Universitaria Careggi), Francesco Di Costanzo, Giuliana Restante(University of Pisa), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Marcello Tiseo(University of Parma), Lorenzo Belluomini(University of Ferrara), Enrico Vasile(Azienda Ospedaliera Universitaria Pisana), Riccardo Morganti(Azienda Ospedaliera Universitaria Pisana), C. Steendam(Erasmus MC), Ron H. N. van Schaik(Erasmus MC), Antonio Chella(Azienda Ospedaliera Universitaria Pisana)
Cited by 12
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k